Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 18/20 | 0.61 |
| ▸ | CHUK | O15111 | 17/20 | 0.58 |
| ▸ | TYK2 | P29597 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 3/20 | 0.43 |
| ▸ | BTK | Q06187 | 3/20 | 0.43 |
| ▸ | ITK | Q08881 | 3/20 | 0.43 |
| ▸ | IKBKE | Q14164 | 3/20 | 0.43 |
| ▸ | PLK1 | P53350 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3542136 | 0.90 | IKBKB (0.67) | IKBKBCHUKCDK2BTKITK | |
| SCHEMBL3543788 | 0.89 | IKBKB (0.65) | IKBKBCHUKTYK2CDK2BTK | |
| SCHEMBL3553685 | 0.85 | IKBKB (0.42) | IKBKBCHUKTYK2 | |
| SCHEMBL3544776 | 0.85 | IKBKB (0.47) | IKBKBCHUKMAP4K4 | |
| SCHEMBL3548555 | 0.85 | IKBKB (0.60) | IKBKBCHUKCDK2BTKITK | |
| Hydrochloric Acid SCHEMBL3546341 | 0.84 | IKBKB (0.46) | IKBKBCHUKMAP4K4 | |
| SCHEMBL3881910 | 0.81 | IKBKB (0.58) | IKBKBCHUKCDK2BTKITK | |
| SCHEMBL14543180 | 0.80 | IKBKB (0.57) | IKBKBCHUKCDK2BTKITK | |
| SCHEMBL3545712 | 0.80 | IKBKB (0.68) | IKBKBCHUKCDK2BTKITK | |
| SCHEMBL3546468 | 0.79 | IKBKB (0.56) | IKBKBCHUKCDK2BTKITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7683171-B2 | N,1-Dimethyl-7-phenyl-1H-imidazo[4,5-d]thieno[3,2-b]pyridin-4-amine; treating inflammatory and immune diseases; cancer; I kappa B kinase (IKK) inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-03-23 | — | — | US | claimed |
| US-7683171-B2 | N,1-Dimethyl-7-phenyl-1H-imidazo[4,5-d]thieno[3,2-b]pyridin-4-amine; treating inflammatory and immune diseases; cancer; I kappa B kinase (IKK) inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683171-B2 | N,1-Dimethyl-7-phenyl-1H-imidazo[4,5-d]thieno[3,2-b]pyridin-4-amine; treating inflammatory and immune diseases; cancer; I kappa B kinase (IKK) inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-03-23 | — | — | US | disclosed |
| WO-2007044050-A2 | 1H-IMIDAZO[4,5-D]THIENO[3,2-B]PYRIDINE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-19 | — | — | WO | disclosed |
| US-20060178393-A1 | 1H-imidazo[4,5-d]thieno[3,2-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178393-A1 | 1H-imidazo[4,5-d]thieno[3,2-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | IL4, IL5, IRAK4 | IKBKB 237/4885CHUK 828/4885TYK2 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.